Oral
Acute uncomplicated cystitis in women
Adult: As fosfomycin trometamol granules: 3 g (fosfomycin base) as a single dose.
Child: >12 years Same as adult dose.
Renal impairment: Patients undergoing haemodialysis: Contraindicated.
CrCl (ml/min) | Dosage Recommendation |
<10 | Contraindicated. |
Reconstitution: Granules for oral solution: Dissolve the contents of a sachet in appropriate volume of water as indicated on the label.
Oral
Prophylaxis of urinary tract infections
Adult: In diagnostic and surgical transurethral procedures: As fosfomycin trometamol granules: 3 g (fosfomycin base) to be given 3 hours before procedure. May give another 3 g, 24 hours after procedure.
Renal impairment: Patients undergoing haemodialysis: Contraindicated.
CrCl (ml/min) | Dosage Recommendation |
<10 | Contraindicated. |
Reconstitution: Granules for oral solution: Dissolve the contents of a sachet in appropriate volume of water as indicated on the label.
Intravenous
Hospital-acquired pneumonia
Adult: As fosfomycin disodium: In cases where commonly recommended agents for initial treatment is considered inappropriate or ineffective: 12-24 g (fosfomycin base) daily, given in 2-3 divided doses; high-dose regimen is used in severe infections known or suspected to be caused by less sensitive organisms. Max: 8 g/dose. Treatment duration may vary depending on the type or severity of infection and patient's response. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Child: Premature neonates <40 weeks (sum of gestational and postnatal age) 100 mg/kg daily, given in 2 divided doses; Neonates 40-44 weeks (sum of gestational and postnatal age) 200 mg/kg daily, given in 3 divided doses; 1-12 months weighing <10 kg: 200-300 mg/kg daily, given in 3 divided doses; 1-<12 years weighing 10-40 kg: 200-400 mg/kg daily, given in 3-4 divided doses; ≥12 years weighing ≥40 kg: Same as adult dose. May consider high-dose regimen for severe infections suspected or known to be caused by organisms with moderate susceptibility. Doses are expressed as fosfomycin base. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: Patient undergoing chronic intermittent haemodialysis (every 48 hours): Give 2 g at the end of each session.
CrCl (ml/min) | Dosage Recommendation |
10 | Give 20% of the usual daily dose in 1-2 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
20 | Give 40% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
30 | Give 60% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
40 | Give 70% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
Reconstitution: Powder for solution for infusion: Reconstitute then dilute with appropriate amount of water for inj, dextrose 5% or 10% inj to prepare the desired concentration. Instruction for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Osteomyelitis
Adult: As fosfomycin disodium: In cases where commonly recommended agents for initial treatment is considered inappropriate or ineffective: 12-24 g (fosfomycin base) daily, given in 2-3 divided doses; high-dose regimen is used in severe infections known or suspected to be caused by less sensitive organisms. Max: 8 g/dose. Treatment duration may vary depending on the type or severity of infection and patient's response. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Child: Premature neonates <40 weeks (sum of gestational and postnatal age) 100 mg/kg daily, given in 2 divided doses; Neonates 40-44 weeks (sum of gestational and postnatal age) 200 mg/kg daily, given in 3 divided doses; 1-12 months weighing <10 kg: 200-300 mg/kg daily, given in 3 divided doses; 1-<12 years weighing 10-40 kg: 200-400 mg/kg daily, given in 3-4 divided doses; ≥12 years weighing ≥40 kg: Same as adult dose. May consider high-dose regimen for severe infections suspected or known to be caused by organisms with moderate susceptibility. Doses are expressed as fosfomycin base. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: Patient undergoing chronic intermittent haemodialysis (every 48 hours): Give 2 g at the end of each session.
CrCl (ml/min) | Dosage Recommendation |
10 | Give 20% of the usual daily dose in 1-2 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
20 | Give 40% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
30 | Give 60% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
40 | Give 70% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
Reconstitution: Powder for solution for infusion: Reconstitute then dilute with appropriate amount of water for inj, dextrose 5% or 10% inj to prepare the desired concentration. Instruction for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Bone and joint infections
Adult: As fosfomycin disodium: In cases where commonly recommended agents for initial treatment is considered inappropriate or ineffective: 12-24 g (fosfomycin base) daily, given in 2-3 divided doses; high-dose regimen is used in severe infections known or suspected to be caused by less sensitive organisms. Max: 8 g/dose. Treatment duration may vary depending on the type or severity of infection and patient's response. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Child: Premature neonates <40 weeks (sum of gestational and postnatal age) 100 mg/kg daily, given in 2 divided doses; Neonates 40-44 weeks (sum of gestational and postnatal age) 200 mg/kg daily, given in 3 divided doses; 1-12 months weighing <10 kg: 200-300 mg/kg daily, given in 3 divided doses; 1-<12 years weighing 10-40 kg: 200-400 mg/kg daily, given in 3-4 divided doses; ≥12 years weighing ≥40 kg: Same as adult dose. May consider high-dose regimen for severe infections suspected or known to be caused by organisms with moderate susceptibility. Doses are expressed as fosfomycin base. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: Patient undergoing chronic intermittent haemodialysis (every 48 hours): Give 2 g at the end of each session.
CrCl (ml/min) | Dosage Recommendation |
10 | Give 20% of the usual daily dose in 1-2 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
20 | Give 40% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
30 | Give 60% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
40 | Give 70% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
Reconstitution: Powder for solution for infusion: Reconstitute then dilute with appropriate amount of water for inj, dextrose 5% or 10% inj to prepare the desired concentration. Instruction for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Complicated urinary tract infections
Adult: As fosfomycin disodium: In cases where commonly recommended agents for initial treatment is considered inappropriate or ineffective: 12-24 g (fosfomycin base) daily, given in 2-3 divided doses; high-dose regimen is used in severe infections known or suspected to be caused by less sensitive organisms. Max: 8 g/dose. Treatment duration may vary depending on the type or severity of infection and patient's response. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Child: Premature neonates <40 weeks (sum of gestational and postnatal age) 100 mg/kg daily, given in 2 divided doses; Neonates 40-44 weeks (sum of gestational and postnatal age) 200 mg/kg daily, given in 3 divided doses; 1-12 months weighing <10 kg: 200-300 mg/kg daily, given in 3 divided doses; 1-<12 years weighing 10-40 kg: 200-400 mg/kg daily, given in 3-4 divided doses; ≥12 years weighing ≥40 kg: Same as adult dose. May consider high-dose regimen for severe infections suspected or known to be caused by organisms with moderate susceptibility. Doses are expressed as fosfomycin base. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: Patient undergoing chronic intermittent haemodialysis (every 48 hours): Give 2 g at the end of each session.
CrCl (ml/min) | Dosage Recommendation |
10 | Give 20% of the usual daily dose in 1-2 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
20 | Give 40% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
30 | Give 60% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
40 | Give 70% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
Reconstitution: Powder for solution for infusion: Reconstitute then dilute with appropriate amount of water for inj, dextrose 5% or 10% inj to prepare the desired concentration. Instruction for reconstitution may vary among individual products and between countries (refer to specific product guidelines).
Intravenous
Bacterial meningitis
Adult: As fosfomycin disodium: In cases where commonly recommended agents for initial treatment is considered inappropriate or ineffective: 16-24 g (fosfomycin base) daily, given in 3-4 divided doses; high-dose regimen is used in severe infections known or suspected to be caused by less sensitive organisms. Max: 8 g/dose. Treatment duration may vary depending on the type or severity of infection and patient's response. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Child: Premature neonates <40 weeks (sum of gestational and postnatal age) 100 mg/kg daily, given in 2 divided doses; Neonates 40-44 weeks (sum of gestational and postnatal age) 200 mg/kg daily, given in 3 divided doses; 1-12 months weighing <10 kg: 200-300 mg/kg daily, given in 3 divided doses; 1-<12 years weighing 10-40 kg: 200-400 mg/kg daily, given in 3-4 divided doses; ≥12 years weighing ≥40 kg: Same as adult dose. May consider high-dose regimen for severe infections suspected or known to be caused by organisms with moderate susceptibility. Doses are expressed as fosfomycin base. Method of administration may vary among individual products and between countries (refer to specific product guidelines).
Renal impairment: Patient undergoing chronic intermittent haemodialysis (every 48 hours): Give 2 g at the end of each session.
CrCl (ml/min) | Dosage Recommendation |
10 | Give 20% of the usual daily dose in 1-2 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
20 | Give 40% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
30 | Give 60% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
40 | Give 70% of the usual daily dose in 2-3 divided doses. 1st dose (loading dose) should be doubled; Max 8 g. |
Reconstitution: Powder for solution for infusion: Reconstitute then dilute with appropriate amount of water for inj, dextrose 5% or 10% inj to prepare the desired concentration. Instruction for reconstitution may vary among individual products and between countries (refer to specific product guidelines).